These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32256074)

  • 21. Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan.
    Hatano M; Takeuchi I; Yamashita K; Morita A; Tozawa K; Sakakibara T; Hajitsu G; Hanya M; Yamada S; Iwata N; Kamei H
    Clin Psychopharmacol Neurosci; 2021 Nov; 19(4):610-617. PubMed ID: 34690116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH; Kim SY; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models.
    Rossi A; Pacifico R; Stratta P
    Patient Prefer Adherence; 2009 Nov; 3():305-9. PubMed ID: 19936173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.
    Lambert M; Conus P; Eide P; Mass R; Karow A; Moritz S; Golks D; Naber D
    Eur Psychiatry; 2004 Nov; 19(7):415-22. PubMed ID: 15504648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.
    Hofer A; Kemmler G; Eder U; Honeder M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2002 Jan; 63(1):49-53. PubMed ID: 11838626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender differences in attitudes towards antipsychotic medications in patients with schizophrenia.
    Zhou J; Xiang YT; Li Q; Zhu X; Li W; Ungvari GS; Ng CH; Ongur D; Wang X
    Psychiatry Res; 2016 Nov; 245():276-281. PubMed ID: 27565699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychotic Symptoms and Attitudes toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up.
    Zheng Y; Ning Y; She S; Deng Y; Chen Y; Yi W; Lu X; Chen X; Li J; Li R; Zhang J; Xiao D; Wu H; Wu C
    Psychopathology; 2018; 51(3):167-176. PubMed ID: 29444522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cultural translation and Tunisian validation of the Drug Attitude Inventory (DAI-30) in outpatients with schizophrenia.
    Nakhli J; Amamou B; Mlika S; Bouhlel S; Trifi M; Nasr SB; El Kissi Y; Ali BB
    Compr Psychiatry; 2015 Jan; 56():69-74. PubMed ID: 25270281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study.
    Hashimoto N; Toyomaki A; Honda M; Miyano S; Nitta N; Sawayama H; Sugawara Y; Uemura K; Tsukamoto N; Koyama T; Kusumi I
    Ann Gen Psychiatry; 2015; 14(1):1. PubMed ID: 25632293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Bindman J; Leese M; Schene A; Becker T; Angermeyer MC; Koeter M; Gray R; Tansella M
    Int Clin Psychopharmacol; 2006 Mar; 21(2):73-9. PubMed ID: 16421457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients.
    Fischel T; Krivoy A; Kotlarov M; Zemishlany Z; Loebstein O; Jacoby H; Weizman A
    Eur Psychiatry; 2013 Aug; 28(6):340-3. PubMed ID: 22999435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Alliance in Patients With Schizophrenia: Introduction of a New Rating Instrument.
    Widschwendter CG; Hofer A; Baumgartner S; Edlinger M; Kemmler G; Rettenbacher MA
    J Psychiatr Pract; 2016 Jul; 22(4):298-307. PubMed ID: 27427841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia.
    Zhang J; Rosenheck R; Mohamed S; Zhou Y; Chang Q; Ning Y; He H
    Compr Psychiatry; 2014 Nov; 55(8):1914-9. PubMed ID: 25217308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insight across mental disorders: A multifaceted metacognitive phenomenon.
    Konstantakopoulos G
    Psychiatriki; 2019; 30(1):13-16. PubMed ID: 31115349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders.
    Leijala J; Kampman O; Suvisaari J; Eskelinen S
    BMC Psychiatry; 2021 Jan; 21(1):37. PubMed ID: 33441112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.